Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Total Liabilities (2018 - 2025)

Historic Total Liabilities for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to $590.8 million.

  • TransMedics' Total Liabilities rose 263.72% to $590.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $590.8 million, marking a year-over-year increase of 263.72%. This contributed to the annual value of $575.5 million for FY2024, which is 116.52% up from last year.
  • Per TransMedics' latest filing, its Total Liabilities stood at $590.8 million for Q3 2025, which was up 263.72% from $572.4 million recorded in Q2 2025.
  • In the past 5 years, TransMedics' Total Liabilities ranged from a high of $590.8 million in Q3 2025 and a low of $48.1 million during Q1 2021
  • Moreover, its 5-year median value for Total Liabilities was $545.1 million (2023), whereas its average is $332.4 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first plummeted by 424.36% in 2021, then surged by 72142.21% in 2023.
  • TransMedics' Total Liabilities (Quarter) stood at $67.0 million in 2021, then skyrocketed by 33.91% to $89.8 million in 2022, then surged by 533.66% to $568.8 million in 2023, then increased by 1.17% to $575.5 million in 2024, then rose by 2.67% to $590.8 million in 2025.
  • Its Total Liabilities stands at $590.8 million for Q3 2025, versus $572.4 million for Q2 2025 and $571.2 million for Q1 2025.